87 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
29039662	62	Quest for Novel Chemical Entities through Incorporation of Silicon in Drug Scaffolds.	Csir-National Chemical Laboratory
21740106	4	A screening assay for neuraminidase inhibitors using neuraminidases N1 and N3 from a baculovirus expression system.	Chulalongkorn University
15772071	3	Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.	Berlex Biosciences
12694187	9	Optimization of P1-P3 groups in symmetric and asymmetric HIV-1 protease inhibitors.	Uppsala University
15837308	19	Oximinoarylsulfonamides as potent HIV protease inhibitors.	Abbott Laboratories
8709110	27	Bis tertiary amide inhibitors of the HIV-1 protease generated via protein structure-based iterative design.	Agouron Pharmaceuticals
8568831	42	Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands.	Eli Lilly
8360874	19	Potent HIV protease inhibitors: the development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligands.	Merck Research Laboratories
12951118	24	HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.	Merck Research Laboratories
12852969	13	The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.	Merck Research Laboratories
12852968	17	HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.	Merck Research Laboratories
14592500	29	Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.	Merck Research Laboratories
15324882	28	P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1.	Merck Research Laboratories
16203148	15	Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.	Merck Research Laboratories
16298527	10	Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.	University of Pennsylvania
16220977	9	Hydroxyethylene sulfones as a new scaffold to address aspartic proteases: design, synthesis, and structural characterization.	Philipps-Universitat Marburg
9871711	22	The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitors.	Dupont Pharmaceuticals
8667359	36	Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors.	Dupont Pharmaceuticals
9154969	20	Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis.	Dupont Pharmaceuticals
15013001	10	Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.	Glaxosmithkline
15533054	24	Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides.	Glaxosmithkline
15653343	20	Cyclic sulfamide HIV-1 protease inhibitors, with sidechains spanning from P2/P2' to P1/P1'.	Uppsala University
9629473	34	Structure-activity relationship of HIV-1 protease inhibitors containing AHPBA. Part III: Modification of P2 site.	Sankyo
8879560	22	Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA--II. Modification of pyrrolidine ring at P1' proline.	Sankyo
10530956	45	Structure-activity relationship of HIV-1 protease inhibitors containing alpha-hydroxy-beta-amino acids. Detailed study of P1 site.	Sankyo
7724556	15	Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus protease.	Agouron Pharmaceuticals
8709109	18	Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease: secondary amide series.	Agouron Pharmaceuticals
8894098	20	Discovery and optimization of nonpeptide HIV-1 protease inhibitors.	Parke-Davis Pharmaceutical Research
10465549	21	Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.	Parke-Davis Pharmaceutical Research
9371233	24	Synthesis of 5,6-dihydro-4-hydroxy-2-pyrones as HIV-1 protease inhibitors: the profound effect of polarity on antiviral activity.	Parke-Davis Pharmaceutical Research
7699705	19	Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H- pyran-3-yl)thiomethanes that span P1-P2' subsites in a unique mode of active site binding.	Parke-Davis Pharmaceutical Research
10658583	50	Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor.	Parke-Davis Pharmaceutical Research
7658450	20	Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors.	Upjohn
9371244	59	4-hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease.	Parke-Davis Pharmaceutical Research
9836627	9	Stereoisomers of cyclic urea HIV-1 protease inhibitors: synthesis and binding affinities.	Dupont Pharmaceuticals
9089336	77	Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.	Upjohn
9216835	30	Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.	Boehringer Ingelheim (Canada)
8642565	36	Inhibitors of human immunodeficiency virus type 1 protease containing 2-aminobenzyl-substituted 4-amino-3-hydroxy-5-phenylpentanoic acid: synthesis, activity, and oral bioavailability.	Sandoz Research Institute
8691434	25	Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.	Upjohn
9083477	11	Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities.	Uppsala University
1588552	30	HIV-1 protease inhibitors based on hydroxyethylene dipeptide isosteres: an investigation into the role of the P1' side chain on structure-activity.	Merck Research Laboratories
9719600	21	Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class.	Upjohn
8064795	29	A novel nonpeptide HIV-1 protease inhibitor: elucidation of the binding mode and its application in the design of related analogs.	Parke-Davis Pharmaceutical Research
7932531	55	Inhibitors of HIV-1 proteinase containing 2-heterosubstituted 4-amino-3-hydroxy-5-phenylpentanoic acid: synthesis, enzyme inhibition, and antiviral activity.	Sandoz Forschungsinstitut Ges.M.B.H.
8021916	11	Aminodiol HIV protease inhibitors. 1. Design, synthesis, and preliminary SAR.	Bristol-Myers Squibb
8057276	11	Crystal-structure-based design and synthesis of novel C-terminal inhibitors of HIV protease.	Agouron Pharmaceuticals
8295206	6	Design and synthesis of peptidomimetic inhibitors of HIV-1 protease and renin. Evidence for improved transport.	University of Pennsylvania
1588551	21	Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.	Merck Research Laboratories
2002466	13	Benzocycloalkyl amines as novel C-termini for HIV protease inhibitors.	Merck Sharp and Dohme Research Laboratories
	50	Potent, orally bioavailable HIV-1 protease inhibitors containing noncoded D-amino acids	Eli Lilly
8494379	4	In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine.	National Cancer Institute-Bethesda
7783120	12	Use of medium-sized cycloalkyl rings to enhance secondary binding: discovery of a new class of human immunodeficiency virus (HIV) protease inhibitors.	Upjohn
7932546	5	Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors.	Upjohn
8544171	5	Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.	Upjohn
8171040	10	L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.	Merck Research Laboratories
8765512	25	Paracyclophanes: a novel class of water-soluble inhibitors of HIV proteinase.	Sandoz Research Institute
2002465	14	L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor.	Merck Research Laboratories
10737742	23	2',6'-Dimethylphenoxyacetyl: a new achiral high affinity P(3)-P(2) ligand for peptidomimetic-based HIV protease inhibitors.	Boehringer Ingelheim Pharmaceuticals
10346931	18	Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.	Japan Energy
11585445	10	Synthesis of potent C(2)-symmetric, diol-based hiv-1 protease inhibitors. Investigation of thioalkyl and thioaryl P1/P1' substituents.	Stockholm University
8642558	30	Aminodiol HIV protease inhibitors. Synthesis and structure-activity relationships of P1/P1' compounds: correlation between lipophilicity and cytotoxicity.	Bristol-Myers Squibb
8230099	29	Synthesis and structure-activity relationships of a series of penicillin-derived HIV proteinase inhibitors containing a stereochemically unique peptide isostere.	Glaxo Group Research
8230098	46	A series of penicillin derived C2-symmetric inhibitors of HIV-1 proteinase: synthesis, mode of interaction, and structure-activity relationships.	Glaxo Group Research
11585446	6	Synthesis of novel, potent, diol-based HIV-1 protease inhibitors via intermolecular pinacol homocoupling of (2S)-2-benzyloxymethyl-4-phenylbutanal.	Stockholm University
8765511	14	Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.	University of Illinois At Chicago
8893827	17	Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors.	Upjohn
8164260	23	The development of cyclic sulfolanes as novel and high-affinity P2 ligands for HIV-1 protease inhibitors.	Merck Research Laboratories
8642563	18	Discovery of novel, non-peptide HIV-1 protease inhibitors by pharmacophore searching.	National Institutes of Health
8423599	26	Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere.	Monsanto Corporate Research
10715152	151	5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.	Parke-Davis Pharmaceutical Research
8423600	13	3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors.	Merck Research Laboratories
8464047	14	Cyclic sulfolanes as novel and high affinity P2 ligands for HIV-1 protease inhibitors.	Merck Research Laboratories
11543677	20	Design and synthesis of potent C(2)-symmetric diol-based HIV-1 protease inhibitors: effects of fluoro substitution.	Linkoping University
11170625	25	Synthesis and comparative molecular field analysis (CoMFA) of symmetric and nonsymmetric cyclic sulfamide HIV-1 protease inhibitors.	Uppsala University
	35	SYNTHESIS AND PHARMACOKINETICS OF POTENT CARBAMATE HIV-1 PROTEASE INHIBITORS CONTAINING NOVEL HIGH AFFINITY HYDROXYETHYLAMINE ISOSTERES	Eli Lilly
	35	Cycloalkylpiperazines as HIV-1 Protease Inhibitors: Enhanced Oral Absorption	Merck Research Laboratories
8759643	17	Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability.	Ciba-Geigy
	4	INFLUENCE OF STEREOCHEMISTRY ON ACTIVITY AND BINDING MODES FOR C(2) SYMMETRY-BASED DIOL INHIBITORS OF HIV-1 PROTEASE.	Nci-Fcrdc
2200122	1	Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.	Abbott Laboratories
8558507	7	A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.	Abbott Laboratories